What’s SMAT®️?
Our state-of-the-art coagulation test “Smart Analysis of Thrombin Production: SMAT” enables rapid and precise assessment of the initial FIIa generation in plasma.
Translating our breakthrough research
findings on thrombosis, hemostasis, and vascular biology.
Create the groundbreaking medical technology for patients
We have created coagulation test technologies and developed the novel assay “The Smart Analysis of Thrombin Production:SMAT" for assessing thrombotic and bleeding diseases. Also, We are currently developing the simple and quick bedside test device for the early detection of patients with thrombosis and bleeding diseases in emergency medical care.
Our products and technology aim to help overcome various thrombus-associated diseases by the early identification of patients with high risk of thrombosis and bleeding diseases, thereby contributing to the extension of healthy life expectancy.
We bring our thrombosis research to life,
transforming the current era of treating thrombotic and bleeding diseases into a new era of preventing from them, ultimately extending healthy life expectancy.
President and CEO
Yuichi Kamikubo
EMPLOYMENT HISTORY:
2019 - present Thrombo Translational Research Lab. Inc., Kumamoto, Japan CEO and President
2003 - 2019 The Scripps Research Institute, La Jolla, USA
1984 - 2003 The Chemo-Sero-Therapeutic Research Institute, Kumamoto, Japan
Visualizing Initial Thrombin Generation
Unlike conventional tests for assessing coagulation reactions
during amplification and propagation phases,
SMAT assay is the specific tool for measuring the tiny amounts of thrombin (FIIa)
generated in the INITIAL coagulation phase.
The assay allows to visualize the risks of thrombus
related diseases to the initial FIIa is a key
for determining the extent of coagulation and thrombus formation.
Highly sensitive blood coagulation assay
"®️SMAT(Smart Analysis of Thrombin Production)"
Our state-of-the-art coagulation test “Smart Analysis of Thrombin Production: SMAT” enables rapid and precise assessment of the initial FIIa generation in plasma.
01Next-gen thrombosis assessment and data analysis
02R&D support services（SMAT®）
03Outsourcing services
